{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:38:34Z","timestamp":1776314314744,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019472","name":"Stichting Kwaliteitsgelden Medisch Specialisten","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114262","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:17:31Z","timestamp":1722701851000},"page":"114262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?"],"prefix":"10.1016","volume":"209","author":[{"given":"N.S.H.","family":"Xander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Leeneman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.E.","family":"Fiets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.K.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.E.M.","family":"Uyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.N.M.","family":"Wymenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2024.114262_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.816","article-title":"Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis","volume":"9","author":"Farina","year":"2021","journal-title":"Pharm Res Perspect"},{"key":"10.1016\/j.ejca.2024.114262_bib2","first-page":"1341","article-title":"Randomized clinical trials - a matter of design","volume":"12","author":"Spieth","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"10.1016\/j.ejca.2024.114262_bib3","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/S1470-2045(16)30572-1","article-title":"Relevance of randomised controlled trials in oncology","volume":"17","author":"Tannock","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114262_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2018-024895","article-title":"Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review","volume":"9","author":"Goring","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ejca.2024.114262_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/cpt.1251","article-title":"Weighing of evidence by health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs","volume":"105","author":"Vreman","year":"2019","journal-title":"Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.ejca.2024.114262_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011666","article-title":"Regulatory approval of pharmaceuticals without a randomised controlled study: Analysis of EMA and FDA approvals 1999-2014","volume":"6","author":"Hatswell","year":"2016","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.ejca.2024.114262_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/cpt.1965","article-title":"Single-arm clinical trials as pivotal evidence for cancer drug approval: a retrospective cohort study of centralized European marketing authorizations between 2010 and 2019","volume":"108","author":"Tenhunen","year":"2020","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.114262_bib8","unstructured":"Nederlandse Vereniging voor Medische Oncologie (NVMO). Over de adviezen - NVMO. https:\/\/www.nvmo.org\/over-de-adviezen\/."},{"key":"10.1016\/j.ejca.2024.114262_bib9","unstructured":"Nederlandse Vereniging voor Medische Oncologie (NVMO). Over de commissie BOM. Nederlandse Vereniging voor Medische Oncologie [Internet]. \u3008https:\/\/www.nvmo.org\/nvmo\/commissie-bom\/over-de-commissie-bom\/\u3009."},{"issue":"8","key":"10.1016\/j.ejca.2024.114262_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2024.114262_bib11","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114262_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114002","article-title":"Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: the impact of different thresholds for effectiveness","volume":"202","author":"Leeneman","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114262_bib13","doi-asserted-by":"crossref","unstructured":"Danen A. \u2018We hebben de lat hoog gelegd.\u2019 Medische Oncologie. doi:10.24078\/onco.2021.5.127336.","DOI":"10.24078\/onco.2021.5.127336"},{"key":"10.1016\/j.ejca.2024.114262_bib14","unstructured":"NVMO-commissie B.O.M. BOM Archieven - NVMO. \u3008https:\/\/www.nvmo.org\/bom-type\/bom\/?order=disease\u3009."},{"issue":"19","key":"10.1016\/j.ejca.2024.114262_bib15","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.114262_bib16","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2024.114262_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.114262_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (Anti\u2013PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.114262_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.114262_bib20","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114262_bib21","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdq618","article-title":"A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer","volume":"22","author":"Reck","year":"2011","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2024.114262_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114262_bib23","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2024.114262_bib24","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2024.114262_bib25","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114262_bib26","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2024.114262_bib27","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur J Cancer"},{"issue":"29","key":"10.1016\/j.ejca.2024.114262_bib28","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2024.114262_bib29","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114262_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2024.114262_bib31","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejca.2024.114262_bib32","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2024.114262_bib33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114262_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2024.114262_bib35","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2024.114262_bib36","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2024.114262_bib37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114262_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2024.114262_bib39","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.114262_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"10064","key":"10.1016\/j.ejca.2024.114262_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2024.114262_bib42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/2159-8290.CD-14-0477","article-title":"Universes collide: combining immunotherapy with targeted therapy for cancer","volume":"4","author":"Wargo","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2024.114262_bib43","doi-asserted-by":"crossref","first-page":"xi32","DOI":"10.1016\/S0923-7534(20)32006-8","article-title":"Results of a global Phase II study with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC)","volume":"23","author":"Kim","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114262_bib44","first-page":"35","article-title":"Selpercatinib als tweedelijnsbehandeling bij gemetastaseerd RET-fusiepositief niet-kleincellig longcarcinoom","volume":"25","author":"NVMO-commissie","year":"2022","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114262_bib45","first-page":"23","article-title":"Entrectinib bij het niet-kleincellig longcarcinoom met een ROS1-genfusie","volume":"25","author":"NVMO-commissie","year":"2022","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114262_bib46","first-page":"17","article-title":"Entrectinib bij solide tumoren met een NTRK-genfusie","volume":"25","author":"NVMO-commissie","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2024.114262_bib47","article-title":"Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy","author":"Michaeli","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"20","key":"10.1016\/j.ejca.2024.114262_bib48","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2024.114262_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJMc2314327","article-title":"Selpercatinib or chemotherapy in RET FUsion\u2013positive NSCLC","volume":"390","author":"Dingemans","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:47:21Z","timestamp":1729615641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":49,"alternative-id":["S0959804924009183"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114262","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114262"}}